---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-229480"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:28:54.405665+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325

## Summary
- Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.
- Plans to focus on SL-325, a first-in-class DR3 antagonist antibody for IBD; IND filing expected Q3 2025.
- Approximately 40% workforce reduction; expects restructuring charges of $1.5M-$1.75M in Q4 2024.
- Cash runway extended into 2027, with $105.3M cash, cash equivalents and investments as of June 30, 2024.
- Mutually terminated collaboration with Ono Pharmaceutical; no future reimbursements, milestones, or royalties.

## SEC filing metadata
- accession: 0001193125-24-229480
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312524229480/0001193125-24-229480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312524229480/d845252d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-229480
- JSON: https://secwatch.observer/filing/0001193125-24-229480.json
- Plain text: https://secwatch.observer/filing/0001193125-24-229480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.